Evidence map›Paper›PMID 37942334›Full record

ArticleFrontiers in immunology2023

Integrated Immunopeptidomic and Proteomic Analysis of COVID-19 lung biopsies.

Shanye Yin, Susan Klaeger, Vipheaviny A Chea, Isabel P Carulli, Suzanna Rachimi, Katharine E Black, Michael Filbin, Lida P Hariri, Rachel S Knipe, Robert F Padera and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Shanye YinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Susan KlaegerBroad Institute of MIT and Harvard, Cambridge, MA, United States.
Vipheaviny A CheaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Isabel P CarulliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Suzanna RachimiBroad Institute of MIT and Harvard, Cambridge, MA, United States.
Katharine E BlackHarvard Medical School, Boston, MA, United States.
Michael FilbinHarvard Medical School, Boston, MA, United States.
Lida P HaririHarvard Medical School, Boston, MA, United States.
Rachel S KnipeHarvard Medical School, Boston, MA, United States.
Robert F PaderaHarvard Medical School, Boston, MA, United States.
Jonathan D StevensDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
William J LaneHarvard Medical School, Boston, MA, United States.
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA, United States.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Edy Yong KimHarvard Medical School, Boston, MA, United States.
Derin B KeskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Harvard University · USBroad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USMassachusetts General Hospital · USBoston University · US

Funding

ProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0M
In vivo endobronchial OCT for IPF diagnosis and therapy response assessmentR01HL152075 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HARIRI, LIDA P · 2020 to 2024
$4.0M
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4M
Systematic identification of minor histocompatibility antigens to address GVHDR01HL157174 · NHLBI · DANA-FARBER CANCER INST · PI HO, VINCENT TRIEN-VINH, KESKIN, DERIN B · 2022 to 2025
$3.0M
Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapyR01CA279391 · NCI · DANA-FARBER CANCER INST · PI Derin B Keskin · 2024 to 2026
$2.2M
Low risk in vivo diagnosis of IPF with optical imagingK23HL132120 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HARIRI, LIDA P · 2016 to 2020
$896k
Role and regulation of vascular permeability in pulmonary fibrosisK08HL140175 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KNIPE, RACHEL S · 2018 to 2022
$864k
Defining the impact of mutational drivers on the immune microenvironment of CLLR21CA267527 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING, YIN, SHANYE · 2022 to 2023
$454k
Histologic and Transcriptional Profiling of Endothelial Cells During Progressive Pulmonary FibrosisR03HL162677 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KNIPE, RACHEL S · 2022 to 2023
$167k
NCI NIH HHS P01 CA206978NCI NIH HHS R01 CA279391NCI NIH HHS R21 CA267527NCI NIH HHS U10 CA180861NHLBI NIH HHS K08 HL140175NHLBI NIH HHS K23 HL132120NHLBI NIH HHS R01 HL152075NHLBI NIH HHS R01 HL157174NHLBI NIH HHS R03 HL162677
6 · The paper itself

Abstract

Introduction: Severe respiratory illness is the most prominent manifestation of patients infected with SARS-CoV-2, and yet the molecular mechanisms underlying severe lung disease in COVID-19 affected patients still require elucidation. Human leukocyte antigen class I (HLA-I) expression is crucial for antigen presentation and the host's response to SARS-CoV-2. Methods: To gain insights into the immune response and molecular pathways involved in severe lung disease, we performed immunopeptidomic and proteomic analyses of lung tissues recovered at four COVID-19 autopsy and six non-COVID-19 transplants. Results: We found signals of tissue injury and regeneration in lung fibroblast and alveolar type I/II cells, resulting in the production of highly immunogenic self-antigens within the lungs of COVID-19 patients. We also identified immune activation of the M2c macrophage as the primary source of HLA-I presentation and immunogenicity in this context. Additionally, we identified 28 lung signatures that can serve as early plasma markers for predicting infection and severe COVID-19 disease. These protein signatures were predominantly expressed in macrophages and epithelial cells and were associated with complement and coagulation cascades. Discussion: Our findings emphasize the significant role of macrophage-mediated immunity in the development of severe lung disease in COVID-19 patients.

Indexed as

COVID-19BiopsyHumansLungProteomicsSARS-CoV-2COVID-19 -HLA-Iimmunopeptidomemacrophageproteomics

Identifiers

PMID37942334
PMCPMC10628763
OpenAlexW4387818024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.